Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Published 22 May 2009, doi:10.1136/bmj.b1668
Cite this as: BMJ 2009;338:b1668
Amanda I Adler, consultant physician 1, Elizabeth J Shaw, technical adviser2, Tim Stokes, associate director2, Francis Ruiz, technical adviser (health economics)3, on behalf of the Guideline Development Group
1 Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ , 2 National Institute for Health and Clinical Excellence, Manchester M1 4BD, 3 National Institute for Health and Clinical Excellence, London WC1V 6NA
Correspondence to: A Adler aia31@medschl.cam.ac.uk
| The first 150 words of the full text of this article appear below. |
Management of type 2 diabetes is complex and aims to prevent and reduce the impact of complications by encouraging a healthy lifestyle, controlling blood pressure and blood lipids, and lowering blood glucose concentrations. In recent years new drugs have become available for blood glucose control, including the long acting insulin analogues (insulin detemir and insulin glargine); glucagon-like peptide-1 (GLP-1) mimetics (exenatide); and dipeptidylpeptidase-4 (DPP-4) inhibitors (sitagliptin and vildagliptin). In addition, safety concerns have surfaced recently about the use of the thiazolidinediones (pioglitazone and rosiglitazone).
This article summarises the most recent recommendations from the National Institute for Health and Clinical Excellence (NICE) on the use of newer agents for control of blood glucose in type 2 diabetes1 and updates the relevant section of the NICE clinical guideline on the management of type 2 diabetes.2
NICE recommendations are based on systematic reviews of best available evidence. When minimal evidence is available, recommendations
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
StumbleUpon
Technorati What's this?